William H. Carson Acquires 3,200 Shares of Annexon, Inc. (NASDAQ:ANNX) Stock

Annexon, Inc. (NASDAQ:ANNX) Director William H. Carson bought 3,200 shares of Annexon stock in a transaction dated Monday, April 8th. The stock was purchased at an average cost of $6.07 per share, for a total transaction of $19,424.00. Following the completion of the acquisition, the director now directly owns 3,200 shares of the company’s stock, valued at approximately $19,424. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Annexon Stock Performance

ANNX opened at $6.07 on Friday. The stock has a market cap of $546.46 million, a price-to-earnings ratio of -3.41 and a beta of 1.14. The stock’s 50 day moving average price is $5.74 and its 200-day moving average price is $3.95. Annexon, Inc. has a one year low of $1.57 and a one year high of $8.40.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Bain Capital Life Sciences Investors LLC grew its stake in shares of Annexon by 41.4% during the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 8,061,719 shares of the company’s stock valued at $36,600,000 after buying an additional 2,359,793 shares during the last quarter. BVF Inc. IL bought a new position in Annexon in the fourth quarter worth approximately $31,780,000. BlackRock Inc. grew its stake in Annexon by 199.7% in the second quarter. BlackRock Inc. now owns 3,479,896 shares of the company’s stock worth $12,249,000 after purchasing an additional 2,318,780 shares in the last quarter. Federated Hermes Inc. grew its stake in Annexon by 50.7% in the first quarter. Federated Hermes Inc. now owns 3,052,651 shares of the company’s stock worth $8,334,000 after purchasing an additional 1,027,051 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in Annexon by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 1,908,326 shares of the company’s stock worth $8,664,000 after purchasing an additional 13,917 shares in the last quarter.

Wall Street Analysts Forecast Growth

ANNX has been the subject of several recent research reports. Needham & Company LLC reiterated a “buy” rating and issued a $16.00 price target on shares of Annexon in a research report on Thursday. JPMorgan Chase & Co. lifted their price target on Annexon from $11.00 to $13.00 and gave the stock an “overweight” rating in a research report on Monday, April 1st. Wells Fargo & Company lifted their price target on Annexon from $11.00 to $12.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 27th. Bank of America lifted their price target on Annexon from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Thursday, March 28th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Annexon in a research report on Wednesday, April 3rd. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, Annexon has a consensus rating of “Buy” and a consensus target price of $14.43.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration.